Advertisement

Topics

FDA Accepts For Review Astellas' Supplemental New Drug Application For Mirabegron For Use In Combination With Solifenacin Succinate 5 Mg For The Treatment Of Overactive Bladder

20:00 EDT 12 Sep 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: FDA Accepts For Review Astellas' Supplemental New Drug Application For Mirabegron For Use In Combination With Solifenacin Succinate 5 Mg For The Treatment Of Overactive Bladder

NEXT ARTICLE

More From BioPortfolio on "FDA Accepts For Review Astellas' Supplemental New Drug Application For Mirabegron For Use In Combination With Solifenacin Succinate 5 Mg For The Treatment Of Overactive Bladder"

Quick Search
Advertisement